King wins Altace case against Lupin
The USA's King Pharmaceuticals says that the US District Court for the Eastern District of Virginia, Norfolk Division, has upheld the validity of its composition of matter patent covering its cardiovascular drug Altace (ramipril). On June 5, the Court granted summary judgment that Lupin's proposed generic product infringed the King's patent.
During the course of trial, the Judge found the patent enforceable, dismissing Lupin's unenforceability claims as a matter of law. James Elrod, King's general counsel, stated: "we are pleased with the Court's decision upholding the validity of King's Altace patent. This decision reinforces the confidence we have continued to express in our intellectual property regarding Altace."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze